Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/30/2019
Start Date:December 18, 2017
End Date:July 30, 2021
Contact:AstraZeneca Clinical Study Information Center
Email:information.center@astrazeneca.com
Phone:1-877-240-9479

Use our guide to learn which trials are right for you!

An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).

This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic
NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in
design, allowing initial assessment of the efficacy, safety, and tolerability of multiple
treatment arms.

This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic
non-small cell lung cancer (NSCLC) who have progressed on an anti-programmed cell
death-1/anti-programmed cell death ligand 1 (anti-PD-1/PD-L1) containing therapy. This study
is modular in design, consisting of a number of treatment cohorts, allowing evaluation of the
efficacy, safety, and tolerability of multiple treatment arms. There is currently no
established therapy for patients who have received immune checkpoint inhibitors and
platinum-doublet therapies, and novel treatments are urgently needed.

This protocol has a modular design, with the potential for future treatment arms to be added
via protocol amendment.

Inclusion criteria:

- At least 18 years of age at the time of signing the informed consent form.

- Patient must have histologically or cytologically confirmed metastatic or locally
advanced and recurrent NSCLC which is progressing.

- Patients eligible for second- or later-line therapy, who must have received an
antiPD1/PD-L1 containing therapy and a platinum-doublet regimen for locally advanced
or metastatic NSCLC either separately or in combination. Prior durvalumab is
acceptable. The patient must have had disease progression on a prior line of
antiPD1/PD-L1 therapy.

- ECOG/WHO performance status of 0 to 1, and a minimum life expectancy of 12 weeks.

- Patient must have at least 1 lesion that can be accurately measured. A previously
irradiated lesion can be considered a target lesion if the lesion has clearly
progressed.

- Evidence of post-menopausal status or negative urinary or serum pregnancy test for
female pre-menopausal patients.

Exclusion Criteria:

- Patients whose tumour samples have targetable alterations in EGFR and/or ALK are
excluded. In addition, patients whose tumour samples are known to have targetable
alterations in ROS1, BRAF, MET or RET, are to be excluded.

- Active or prior documented autoimmune or inflammatory disorders.

- Active infection including hepatitis B (known positive HBV surface antigen [HBsAg]
result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies).

- Female patients who are pregnant or breastfeeding, or male or female patients of
reproductive potential who are not willing to employ effective birth control.

- Known allergy or hypersensitivity to any of the study drugs or any of the study drug
excipients.

- Patient has spinal cord compression or symptomatic brain metastases.

- Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer
treatment. Patients may receive treatment with bisphosphonates or receptor activator
of nuclear factor kappa-Β ligand (RANKL) inhibitors for the treatment of bone
metastases.
We found this trial at
12
sites
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Duarte, CA
Click here to add this to my saved trials
?
mi
from
Fullerton, CA
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Innsbruck,
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials